We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+7.15%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$3.62B
AUM Growth
+$540M
Cap. Flow
+$569M
Cap. Flow %
15.72%
Top 10 Hldgs %
34.44%
Holding
132
New
36
Increased
34
Reduced
15
Closed
38

Top Buys

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$105M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$93.1M
3
MDT icon
Medtronic
MDT
+$84.8M
4
NUVB icon
Nuvation Bio
NUVB
+$84.1M
5
ABBV icon
AbbVie
ABBV
+$77.1M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$137M
2
DGX icon
Quest Diagnostics
DGX
+$94.4M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$87.1M
4
CHNG
Change Healthcare Inc. Common Stock
CHNG
+$57.5M
5
ORGO icon
Organogenesis Holdings
ORGO
+$55M

Sector Composition

Rank Sector Weight
1 Healthcare 95.31%
2 Financials 0.29%
3 Industrials 0%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
101
BioMarin Pharmaceuticals
BMRN
$12B
– –
-992,900
Closed -$87.1M
BTAI icon
102
BioXcel Therapeutics
BTAI
$25.1M
– –
-34,188
Closed -$25.3M
CDXS icon
103
Codexis
CDXS
$158M
– –
-600,000
Closed -$13.1M
CERT icon
104
Certara
CERT
$1.24B
– –
-404,663
Closed -$13.6M
CSTL icon
105
Castle Biosciences
CSTL
$731M
– –
-150,000
Closed -$10.1M
DGX icon
106
Quest Diagnostics
DGX
$26B
– –
-792,100
Closed -$94.4M
INZY
107
DELISTED
Inozyme Pharma
INZY
– –
-9,683
Closed -$200K
ITOS
108
DELISTED
iTeos Therapeutics
ITOS
– –
-92,574
Closed -$3.13M
KROS icon
109
Keros Therapeutics
KROS
$198M
– –
-40,000
Closed -$2.82M
KURA icon
110
Kura Oncology
KURA
$795M
– –
-347,645
Closed -$11.4M
LGND icon
111
Ligand Pharmaceuticals
LGND
$5.88B
– –
-99,546
Closed -$6.18M
LLY icon
112
Eli Lilly
LLY
$1.09T
– –
-810,500
Closed -$137M
NRIX icon
113
Nurix Therapeutics
NRIX
$2.45B
– –
-50,000
Closed -$1.64M
NTLA icon
114
Intellia Therapeutics
NTLA
$1.49B
– –
-303,000
Closed -$16.5M
OCUL icon
115
Ocular Therapeutix
OCUL
$1.85B
– –
-250,000
Closed -$5.17M
OLMA icon
116
Olema Pharmaceuticals
OLMA
$986M
– –
-270,000
Closed -$13M
OM icon
117
Outset Medical
OM
$87.3M
– –
-6,667
Closed -$5.68M
PHAT icon
118
Phathom Pharmaceuticals
PHAT
$938M
– –
-152,500
Closed -$5.07M
RCKT icon
119
Rocket Pharmaceuticals
RCKT
$336M
– –
-50,000
Closed -$2.74M
RLAY icon
120
Relay Therapeutics
RLAY
$3.96B
– –
-30,000
Closed -$1.25M
SGRY icon
121
Surgery Partners
SGRY
$2.13B
– –
-531,000
Closed -$15.4M
SRPT icon
122
Sarepta Therapeutics
SRPT
$1.62B
– –
-217,400
Closed -$37.1M
STRO icon
123
Sutro Biopharma
STRO
$387M
– –
-62,600
Closed -$13.6M
TSHA icon
124
Taysha Gene Therapies
TSHA
$1.55B
– –
-392,000
Closed -$10.4M
ZYME icon
125
Zymeworks
ZYME
$1.63B
– –
-578,100
Closed -$27.3M
2 3 4
5
6

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q1 2021 Portfolio in Review

As of Q1 2021, Avidity Partners Management held 132 positions worth $3.62B, up 18% from $3.08B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Avidity Partners Management deployed $569M of net new capital in Q1 2021, opening 36 new positions and adding to 34 existing holdings. Its largest new stake was Intuitive Surgical: 418,200 shares worth $103M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 91% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Organogenesis Holdings, an estimated $55M trimmed.

  • Avidity Partners Management's largest Q1 2021 buy was Intuitive Surgical: 418,200 shares worth $103M.
  • Avidity Partners Management added most to Medtronic in Q1 2021, an estimated $84.8M increase.
  • Avidity Partners Management's biggest Q1 2021 reduction was Organogenesis Holdings, cutting an estimated $55M.
  • Avidity Partners Management fully exited Eli Lilly in Q1 2021, selling an estimated $137M.
  • Avidity Partners Management's ten largest holdings make up 34% of its $3.62B portfolio in Q1 2021.
  • Avidity Partners Management opened 36 new positions and closed 38 in Q1 2021.
  • Avidity Partners Management's portfolio value rose 18% quarter-over-quarter to $3.62B.

Based on Avidity Partners Management's 13F filing for Q1 2021, filed 17 May 2021.